Janssen's hepatitis C drug gets FDA panel endorsement

10/25/2013 | Medscape (free registration) · PharmaTimes (U.K.)

An FDA panel endorsed the approval of Janssen's simeprevir to be used in combination with peginterferon alfa and ribavirin to treat chronic hepatitis C in treatment-naive adults with compensated liver disease. The therapy is also intended for patients who did not respond to previous interferon treatment.

View Full Article in:

Medscape (free registration) · PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD